AbbVie Inc.
📊 Market Data
📈 Income Statement (SEC Verified)
| Metric | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $56.33B | N/A | N/A | N/A | $61.16B | N/A |
| Net Income | $1.37B | $1.56B | $-22.00M | $1.29B | $938.00M | $186.00M | $1.82B | $695.00M |
| EPS (Diluted) | $0.77 | $0.88 | $-0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 |
💹 Profitability & Margins
🏦 Balance Sheet
💸 Cash Flow Statement
🎯 Analyst Ratings & Price Targets
Consensus Recommendation
BuyBased on 29 analyst opinions
| Target High | $328.00 |
| Target Mean | $252.90 |
| Target Low | $184.00 |
| Current Price | $209.41 |
| Upside Potential | +20.8% |
🏢 Company Information
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; ...
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Employees | 57,000 |
| Headquarters | North Chicago, IL, United States |
| Website | https://www.abbvie.com |
| Exchange | NYQ |
| Currency | USD |
| Shares Outstanding | 1.77B |
| Insider Ownership | 0.1% |
| Institutional Ownership | 76.8% |
| EPS (TTM) | 2.03 |
| EPS (Forward) | 16.23 |
| PEG Ratio | 0.58 |
| Next Earnings Date | 2026-04-29 |